PathogenDx Introduces Urinary Tract Infection PCR Test

PathogenDx has launched the D³ Array-UTI, a differentiated multiplexed PCR test that detects 26 pathogens and 12 antibiotic resistance gene markers to help clinicians rapidly treat urinary tract infections (UTI). Powered by the company’s multiplexed molecular diagnostics technology, D³ Array-UTI features testing in triplicate for quality assurance, with qualitative and quantitative results in the same reaction, as well as automated, cloud-based data analysis, reporting, and management. 
 
“Providing a proper UTI diagnosis is a race against the clock,” PathogenDx Co-Founder/CEO Milan Patel said. “An individual is risking continued pain and discomfort, chronic infections, kidney infection, and in severe cases, sepsis. D³ Array-UTI supersedes current approaches by improving the value proposition for clinical labs on multiple fronts; from optimizing the cost of testing, streamlining analytics and reporting, concentrating all targets in a single well in triplicate, delivering higher throughput without compromising content, and ensuring robust results. This technology is a step forward in addressing some of the inherent challenges laboratories are currently facing in running multiplex qPCR panels for UTIs.” 
 
D³ Array-UTI is the latest addition to the platform of tests based on PathogenDx’s patented Dynamic Dimensional Detection (D³ Array), which combines a microarray architecture that significantly increases sensitivity, with detection and discrimination of pathogens and antibiotic resistant gene markers through rapid concurrent room temperature hybridization. The array is equipment agnostic, making it compatible with routine molecular instrumentation and existing workflow.
 
D³-Array-UTI utilizes a foil-sealed 96-well plate, allowing labs to use only the wells needed without incurring additional cost and waste for unused wells on a plate. Data analysis and reporting is automated using PathogenDx’s Augury proprietary cloud-based data analysis and data management tool, reducing the time and cost of deciphering results. 
 
Headquartered in Scottsdale, Ariz., PathogenDx develops next-generation microarray technology that can rapidly detect and identify up to 50 pathogens simultaneously, in a single test, in six hours providing triplicate data per analyte.